FUJIFILM Announces Agreement to Acquire Kalon Biotherapeutics

FUJIFILM Corp. will enter the vaccine CMO market with the acquisition of Kalon Biotherapeutics, a biologics development and manufacturing service provider out of Texas. FUJIFILM subsidiary, FUJIFILM Diosynth Biotechnologies (FDBU), will acquire 49% of the total membership interests in Kalon and will be entitled to appoint a majority of Kalon’s board members. Based on milestone achievements, FDBU may acquire 100% interest share.

The acquisition will strengthen FUJIFILM’s stance in the pharmaceutical industry. This announcement comes shortly after the announcement that FUJIFILM would start producing Avigan, an experimental treatment for Ebola.

Source: FUJIFILM